Transgene Biotek has expanded its cancer drug pipeline by coming out with a novel drug for colon cancer. The drug is based on Transgene's proprietary technology platform using a humanised monoclonal antibody. Transgene has developed monoclonal antibodies, which efficiently kill colon cancer cells without harming normal cells.
According to a report from Economic Intelligence Unit, by 2020, 9.7 per cent of new cases of cancer in the world will be from colorectal cancer making it the third highest incidence cancer after lung and breast. Cancer accounted for 7.9 million deaths in 2007, about 70 per cent in low and middle income countries.